Long-Acting Injectable PrEP
Long-acting injectable PrEP is an experimental strategy in efficacy trials. These trials (HPTN 083 and HPTN 084) seek to establish if a bimonthly injection of the antiretroviral cabotegravir is safe and effective at reducing HIV risk among African women, gay men and other men who have sex with men and transgender women in Africa and the Americas. Injectable PrEP might be a preferred choice by individuals who don’t want to take a daily pill.
Data from these trials are expected in 2021-22, and these results will help guide next steps including potential introduction. The same drug is also being tested in combination with another ARV (rilpivirine) as injectable ART for people living with HIV who are stable on treatment. Injectable ARVs could change HIV prevention and treatment in coming years. Watch this space for the latest news.